Previous close | 0.8500 |
Open | 1.8000 |
Bid | 0.0000 |
Ask | 1.7500 |
Strike | 10.00 |
Expiry date | 2024-05-17 |
Day's range | 0.8500 - 1.8000 |
Contract range | N/A |
Volume | |
Open interest | 10 |
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
SAN DIEGO, May 13, 2024--TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery. A new center within the Johns Hopkins Whiting School of Engineering will accelerate research and therapeutic development, leveraging TriLink’s leading RNA synthesis technology.
Maravai LifeSciences Holdings ( NASDAQ:MRVI ) First Quarter 2024 Results Key Financial Results Revenue: US$64.2m (down...